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Imiquimod is a topical toll-like-receptor-7 agonist currently used for treating basal cell carcinoma. 
Recently, imiquimod has demonstrated tumor regression in melanoma and breast cancer skin 
metastases. However, the molecular perturbations induced by imiquimod in breast cancer metastases 
have not been previously characterized. Here, we describe transcriptomic profiles associated with 
responsiveness to imiquimod in breast cancer skin metastases. Baseline and post-treatment tumor 
samples from patients treated with imiquimod in a clinical trial were profiled using Nanostring 
technology. Through an integrative analytic pipeline, we showed that tumors from patients who 
achieved a durable clinical response displayed a permissive microenvironment, substantiated by the 
upregulation of transcripts encoding for molecules involved in leukocyte adhesion and migration, 
cytotoxic functions, and antigen presentation. In responding patients, Imiquimod triggered a strong 
T-helper-1 (Th-1)/cytotoxic immune response, characterized by the coordinated upregulation of 
Th-1 chemokines, migration of Th-1 and cytotoxic T cells into the tumor, and activation of immune-
effector functions, ultimately mediating tumor destruction. In conclusion, we have shown that topical 
imiquimod can induce a robust immune response in breast cancer metastases, and this response is more 
likely to occur in tumors with a pre-activated microenvironment. In this setting, imiquimod could be 
utilized in combination with other targeted immunotherapies to increase therapeutic efficacy.
Breast cancer is the second cause of death in women and the second most common cancer to metastasize to the 
skin after melanoma1. Treatment of breast cancer skin metastases remains a challenge. Initial management usu-
ally consists of resection and radiotherapy but skin metastases often recur and can lead to chest wall ulceration, 
bleeding, and pain.
Imiquimod is a Toll-like Receptor (TLR)-7 agonist that can activate the innate immune system and shape the 
ensuing adaptive immune response. Imiquimod induces the production of several pro-inflammatory cytokines 
such as IFN-α, TNF-α, IL-1, IL-6, and IL-8 and leads to the recruitment and activation of dendritic cells2–4. In 
basal and squamous cell carcinoma, imiquimod induces infiltration of the tumor with effector T cells, increases 
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production of IFN-γ, granzyme, perforin, and apoptosis5,6. Genome-wide transcriptomic analysis of basal cell 
carcinoma before and after treatment has defined key molecular events induced by imiquimod7. Such transcripts 
are involved in the activation of specific chemokine-chemokine receptor ligand pathways conducive to a T-helper 
1 (Th-1) immune response and the induction of immune-effector genes. These pathways are also activated dur-
ing other forms of immunity-mediated tissue-specific destruction, such allograft rejection8, graft-versus-host 
disease and flares of autoimmunity, and were termed as the Immunologic Constant of Rejection (ICR)9–11. The 
ICR signature was further refined and is now represented by twenty transcripts in four functional categories: 
CXCR3/CCR5 chemokines (including CXCL9, CXCL10, CCL5), Th1 signaling (including IFNG, IL12B, TBX21, 
CD8A, STAT1, IRF1, CD8B), effector (including GNLY, PRF1, GZMA, GZMB, GZMH) and immune regulatory 
functions (including CD274, CTLA4, FOXP3, IDO1, PDCD1)12–14. High expression of the ICR has been found 
to be associated with favorable prognosis in multiple tumor types and responsiveness to immunotherapeutic 
approaches such as IL-2, adoptive therapy and checkpoint inhibition10,15–17.
In melanoma, several case reports have shown regression of cutaneous metastases with imiquimod either 
alone18,19 or in combination with other therapies20–22. This tumor regression was associated with an increase in T 
cell infiltrate and upregulation of ICR genes such as CCL5, CXCL9, CXCL10 important for homing of cytotoxic T 
cells as well as markers of dendritic cell (CD80, CD86) and T cell activation (CD69)23.
Activation of the adaptive immune response has been shown to be associated with better prognosis in breast 
cancer. An increase in the number of tumor infiltrating lymphocytes is associated with greater likelihood of com-
plete pathological response after chemotherapy across breast cancer subtypes, and reduced risk of relapse and death 
particularly in triple negative breast cancers24–31. Interestingly, most of the prognostic and predictive transcriptomic 
classifiers described so far in breast cancer include ICR genes. Type I immunity is believed to be especially important 
for immunotherapy, with CD8+ T cells inducing cytotoxicity and CD4+ T helper cells inducing cytokine secretion 
and promotion of antigen presentation of tumor32. In a recent trial, topical imiquimod in combination with intrave-
nous nab-paclitaxel resulted in an antitumor response of 72% in the treatment of mostly hormone receptor negative 
breast cancer cutaneous metastases33 suggesting that activation of the immune system may play an important role 
in the treatment of breast cancer skin metastases. Imiquimod may play an even more important role in hormone 
receptor positive breast cancer, since it is the subtype with the least amount of CD8+ infiltrating T cells34.
We have previously shown that topical imiquimod, as a single agent, can induce an antitumor response in 20% 
of skin metastases of mainly hormone receptor positive breast cancers and can promote an immunogenic tumor 
microenvironment35. An increase in CD4+ and CD8+ infiltrating T cells after treatment was seen in one of the 
responders but not in the other, and cytokine measurement in tumor supernatant was variable, suggesting the 
need for a more sensitive assay to characterize the effects of imiquimod on the tumor microenvironment in breast 
cancer skin metastases. Furthermore, in two additional patients who achieved long-term benefit, an antitumor 
antigen response was induced by imiquimod (in-situ vaccination effect) and subsequently expanded by endocrine 
therapy leading to durable complete remissions.36
Here, by using an integrative analysis we describe transcriptomic profiles associated with responsiveness to 
imiquimod treatment. This is the first study to characterize the transcriptomic changes induced by imiquimod in 
breast cancer skin metastases.
Methods
Patients. Ten patients were enrolled and treated with imiquimod for eight weeks as previously described35. 
The clinical trial was approved by the New York University Institutional Review Board. All research was per-
formed in accordance with the New York University Institutional Review Board guidelines and regulations, a 
written informed consent was obtained from all patients. Same-site tumor biopsies were obtained at baseline and 
after 8 weeks of imiquimod treatment. Paraffin embedded tumor tissue was available from 8/10 patients for this 
study, as samples from two patients had insufficient quantity for further analysis. Two of the patients had stable 
disease during the initial study and were found to have a systemic complete clinical response after subsequent 
treatment with fulvestrant after study completion (including the treated skin metastases). On follow up, these two 
patients also had disease remission for two years. We initially sought to characterize the tumor microenvironment 
of these two patients due to their unusual complete response on hormone therapy and long duration of disease 
remission and labeled these patients as complete responders (CR). An additional patient had a local partial tumor 
response (greater than 50% tumor shrinkage) after eight weeks of imiquimod treatment and was labeled as a par-
tial responder (PR). Patients with CR and PR were considered as having derived clinical benefit (CB). Five of the 
eight patients did not have a clinical response and were defined as non-responders (NR).
Gene Expression. Paraffin blocks were carefully evaluated for tumor content and cut into seven sections of 
10 um thickness for RNA extraction. Samples were deparaffinized with xylene and extracted using the RNeasy 
FFPE kit (Qiagen #73504), according to manufacturer’s instructions. Extracted FFPE RNA quality and quantity 
were analyzed on an agilent Bioanalyzer 2100 using a nano chip. Smear analysis was performed to determine the 
percent of RNA greater than 300nt for optimized hybridization according to Nanostring’s protocol. Adjusted 
inputs for each RNA sample were calculated to input 100 ng of RNA greater than 300nt. RNA was hybridized 
using the Nanostring nCounter® Human v1.1 PanCancer Immune Profiling Panel (770 transcripts) according 
to the manufacturer’s protocol. Hybridizations were processed on the nCounter Prep Station, and prepped car-
tridges were scanned on the Nanostring Digital Analyzer using 280 field of view counts.
Immunohistochemistry. The evaluation of tumor-infiltrating lymphocytes (TIL) density was performed by 
Immunohistochemistry (IHC) on paraffin embedded tumor tissues as previously described35 and correlated with 
clinical response. Tumor sections (thickness 4 μm) were deparaffinized and rinsed in distilled water. Heat induced 
epitope retrieval was carried out in 10 mmol/L citrate buffer. CD3, CD4, CD8 (Ventana Medical Systems), and 
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Forkhead Box Protein P3 antibody (FoxP3, Ebiosciences) antibodies were used. Detection was carried out on a 
NEXes instrument (Ventana Medical Systems) using the manufacturer’s reagent buffer and detection kits. After 
washing in distilled water, slides were counterstained with hematoxylin, dehydrated, and mounted with perma-
nent media. Appropriate positive and negative controls were included with the study sections. IHC-positive cells 
were counted manually in 5 representative high-power fields (HPF, 400), to derive the average number per HPF, 
by a pathologist blinded to the response.
Statistical Analysis. Data were normalized using the housekeeping genes present in the panel and by 
applying negative control subtraction (nSover 2.6 package). Quantile normalization using preprocessCore v1.38 
and Log2 transformation was applied to the expression matrix. PCA plots were generated using scatterplot3d 
v0.3. Consensus clustering based on the ICR genes was performed using consensusclusterPlus v1.40 (maxK = 7, 
5000 repetitions, Ward D2 as interlinking). Based on such clustering, samples were classified as ICR High, ICR 
Medium, and ICR Low, with ICR High and ICR Low samples as the highest and lowest expression of the ICR 
z-score, respectively.
Singe sample gene set enrichment (ssGSEA)37,38 using GSVA package v1.24.2 was applied to calculate 
enrichment scores for leukocyte populations using cell-specific transcripts included in the Nanostring panel 
(Supplementary Table S1) as well as the enrichment score for the ICR genes. The fold changes of these scores were 
expressed as the ratio of Anti Loge of the mean enrichment scores and were plotted with their confidence inter-
val using forestplot v1.7.2. Differentially expressed genes (DEGs) or differences in the enrichment scores were 
calculated by paired or unpaired t-test for the post- vs pre-treatment and CR vs NR analysis respectively using 
2-tailed p value of 0.05 as significance cut off. Fold change was expressed by the Anti-Log2 of the Log2 fold change, 
which is the difference between the mean of the Log2 values of the two categories in comparison. Enrichment 
analysis of the DEGs was performed using Nanostring annotations (immune response categories, Supplementary 
Table S2) specific for this panel. In all comparisons of response status, only the CR and NR samples were included 
as these samples represent tumors with two opposite biologic behaviors. PR data were however displayed in the 
heatmaps and boxplots in comparison with CR and NR samples. Post- vs pre-treatment comparisons were per-
formed by including all samples. Boxplots for single gene expression and ICR score were plotted using ggplot2 v 
2.2.1. Dotted heatmaps were used to represent the ssGSEA enrichment z-scores and the percentage of genes with 
an absolute fold change of more than 1.5 for each immune cell signature. These plots were generated using the 
ComplexHeatmap v1.14 package. Immunohistochemistry data were compared by Wilcoxon signed-rank test.
Results
Patient characteristics. Paired tissues from eight patients with breast cancer skin metastases enrolled on a 
clinical trial of imiquimod therapy were included in this study. Patient demographics are summarized in Table 1. 
The majority of the women were post-menopausal (62.5%), all had invasive ductal carcinoma, and the majority of 
tumors were high grade (87.5%) and hormone receptor positive (87.5%), 50% were HER2 positive. Patients were 
designated as CR (n = 2), PR (n = 1), and NR (n = 5) as described above.
Transcriptome changes induced by imiquimod treatment and baseline predictive markers. 
Principal component analysis (PCA) based on all the transcripts is shown in Fig. 1A. Using a PC1 arbitrary 
cut-off of −10 3/3 tumors from patients responding to the treatment but only 1/5 tumors from non-responding 
patients were found to cluster. The number of overlapping genes among the comparisons used for the detection 
of the DEGs (e.g., post vs pre-treatment, pre-treatment CR vs NR, and post-treatment CR vs NR) are shown in 
Fig. 1B. Comparing all patients post- versus pre-treatment, 53 DEGs were identified (Table 2, Fig. 1B,C). Several 
genes related to innate immunity were upregulated in the post-treatment group. These included genes related to 
lymphocyte activation (SH2D1A, SLAMF1), lymphocyte adhesion (SELL), cytolysis (PRF1), NK cell activation 
(KLRC1), T cell (CD3G, CD347) and cytotoxic T cell (CD8A) function, and antigen presentation (HLA-C). 
Although some genes were downregulated, overall, pathway enrichment analysis revealed a positive modulation 
of the immune response underlined by the activation of cytotoxic mechanisms (Fig. 1D and Supplementary 
Table S3). Downregulated genes included several MAPK-related genes (MAP2K4, MAPK1, MAPK11 and 
ID Age Pathology HR HER2 Grade
Extracutaneous 
metastases Response
1 50 IDC Pos Pos III Lung NR
2 44 IDC Neg Neg III Pleura NR
3 49 IDC Pos Pos III None NR
4 57 IDC Pos Neg III LN NR
5 50 IDC Pos Pos III Adrenal CR
6 49 IDC Pos Neg II Lung, Bone CR
7 57 IDC Pos Pos III Bone NR
8 71 IDC Pos Neg III Bone, LN PR
Table 1. Patient characteristics. ID: identifier, IDC: invasive ductal carcinoma, HR: hormone receptor, HER2: 
human epidermal growth factor receptor, NR: no response, CR: complete response, PR: partial response. Pos: 
positive, Neg: negative.
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Figure 1. Transcriptomic changes according to treatment and response status. (A) Principle component analysis 
(PCA) based on all transcripts. (B) Venn diagrams of DEGs, (separated by down and upregulated, p < 0.05) 
red circles: paired t-test, post- vs pre-treatment samples; blue circles: unpaired t-test, pre-treatment complete 
responder (CR) vs pre-treatment non responder (NR), excluding the partial responder (PR) sample from the 
statistical test; green circles: unpaired t-test, post-treatment complete responder (CR) vs post-treatment non 
responder (NR), excluding the partial responder sample from the statistical test. (C) Heatmaps based on the DEGs 
in B; samples are ordered according to treatment and ICR score in the left panel, and using hierarchical clustering 
in the middle and right panel; the PR sample was clustered according to the DEG as in B; genes are ordered 
according to hierarchical clustering in all panels; Hormone receptor (HR) status, HER2 receptor (HER2) status and 
ICR classification are shown. For the ICR classification, samples were clustered using consensus clustering based 
on 20 ICR genes in 3 groups with low (ICR low), intermediate (ICR medium), and high (ICR high) expression of 
the ICR genes (see methods). (D) Top enriched Nanostring pathways (Immune Response Categories).
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Gene p value q value
FC (Post 
vs Pre) Annotation
SELL 0.0111 0.725 2.212 CD molecules, Regulation of immune response
PRF1 0.0097 0.725 2.119 Adaptive immune response, Cell Type specific, Cytotoxicity, Defense response to tumor cell, Defense response to virus
SH2D1A 0.0259 0.725 2.099 Humoral immune response
TNFRSF13B 0.0152 0.725 1.987 CD molecules, Chemokines and receptors, TNF superfamily members and their receptors
CD3G 0.0326 0.725 1.891 Adaptive immune response, Cell Type specific, CD molecules, Regulation of immune response, T-cell activation
TNFRSF9 0.048 0.725 1.860 CD molecules, TNF superfamily members and their receptors
IRF7 0.0182 0.725 1.813 Innate immune response
CD38 0.0292 0.725 1.733 Adaptive immune response, Cell Type specific, CD molecules, Response to drug, Positive regulation of B-cell proliferation
CD247 0.0116 0.725 1.583 CD molecules, Regulation of immune response
IL1R2 0.0436 0.725 1.551 CD molecules, Cytokines and receptors
KLRC1 0.0035 0.725 1.547 CD molecules, NK cell functions, Regulation of immune response
CDKN1A 0.0443 0.725 1.543 Cell cycle checkpoint and cell cycle arrest, Regulation of cell cycle, Senescence pathway, Senescence initiators interferon related
MEFV 0.0089 0.725 1.543 Innate immune response
CD8A 0.0059 0.725 1.537 Adaptive immune response, Antigen processing and presentation, Cell Type specific, CD molecules, Defense response to virus, T-cell activation, T-cell differentiation
CD6 0.0349 0.725 1.513 Adaptive immune response, Basic cell functions, Cell Type specific, CD molecules
NOD2 0.0322 0.725 1.509 Innate immune response, Cytokines and receptors
FUT7 0.0485 0.725 1.505 Leukocyte migration
SLAMF1 0.0039 0.725 1.477 CD molecules, Adaptive immune response
TNFSF10 0.038 0.725 1.456 CD molecules, Co-Regulators of autophagy and apoptosis/cell cycle, Cytokines and receptors, TNF superfamily members and their receptors
ITGAL 0.0276 0.725 1.452 Adhesion, CD molecules, Regulation of immune response
NLRC5 0.0359 0.725 1.422 Innate immune response
HLA-C 0.0173 0.725 1.397 Adaptive immune response, Antigen processing and presentation, Cytotoxicity, Regulation of immune response
STAT2 0.0331 0.725 1.379 Cytokines and receptors, Transcription factors, Transcriptional regulators
MME 0.0142 0.725 1.299 Basic cell functions, Cell Type specific, CD molecules
CD83 0.0138 0.725 1.273 CD molecules, Humoral immune response
CMKLR1 0.0412 0.725 1.198 Chemokines and receptors
EWSR1 0.02 0.725 0.857 Basic cell functions, Cell Type specific
MAP2K2 0.0088 0.725 0.837 Innate immune response
DDX43 0.0092 0.725 0.792
MICA 0.0182 0.725 0.791 Immune response to tumor cell, Regulation of immune response
MAP3K5 0.0008 0.328 0.788 Innate immune response
CD200 0.0283 0.725 0.782 CD molecules, Regulation of immune response
LTBR 0.0061 0.705 0.780 Chemokines and receptors
PVR 0.0037 0.328 0.767 CD molecules, Regulation of immune response
C5 0.044 0.725 0.729 Complement pathway, Innate immune response
TAB1 0.0277 0.725 0.726 Innate immune response
MAPK11 0.0325 0.725 0.720 Innate immune response
IL17B 0.0201 0.725 0.709 Chemokines and receptors, Interleukins
MAPK1 0.0021 0.705 0.705 Innate immune response
CD164 0.0427 0.725 0.702 CD molecules
NFKBIA 0.043 0.725 0.695 Innate immune response
ILF3 0.0018 0.517 0.675 Chemokines and receptors
IL13RA1 0.0167 0.725 0.627 CD molecules, Cytokines and receptors, Th2 orientation
MST1R 0.0258 0.725 0.621 CD molecules, Innate immune response
MAP2K4 0.0309 0.725 0.618 Innate immune response
APOE 0.0236 0.725 0.594 Cell Type specific, Lipid transporter activity
RPS6 0.043 0.725 0.586 T-cell proliferation
CD9 0.0178 0.725 0.571 CD molecules
TXNIP 0.0434 0.725 0.559 Innate immune response
F13A1 0.0372 0.725 0.507 Basic cell functions, Cell Type specific
DUSP4 0.0337 0.725 0.501 Innate immune response
CMA1 0.0413 0.725 0.421 Cell Type specific, Regulation of inflammatory response
FCER1A 0.0152 0.725 0.336 Inflammatory response
Table 2. DEG post vs pre-treatment. 53 Significant (p < 0.05) DEGs comparing nanostring immune gene 
expression between post- and pre- treatment samples using paired t-test including non responder (NR), 
complete responder (CR) and partial responder (PR) samples. Ordered from high to low fold change 
(Fc = 2^(mean log2 post treatment expression − mean log2 pre treatment expression)).
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MAP3K5), which are also involved in oncogenic signaling, and genes related to IL-17/Th-17 and IL-13 signaling 
(Table 2 and Supplementary Table S3).
In baseline samples, prior to treatment with imiquimod, 45 genes were differentially expressed in CR vs NR 
samples (Table 3, Fig. 1B). Interestingly, the PR clustered between CR and NR (Fig. 1C). Upregulated genes 
included leukocyte adhesion and migration molecules (ITGAX, ITGAM, ITGB2, and FUY7), chemokine 
Gene p value q value
FC (CR 
vs NR) Annotation
CFB 0.00341 0.256 7.534 Innate immune response
DUSP4 0.00981 0.368 7.489 Innate immune response
MPPED1 0.00008 0.047 4.988 Basic cell functions, Cell Type specific
HLA-DPA1 0.00137 0.163 3.120 Adaptive immune response, Antigen processing and presentation
ITGAX 0.03974 0.638 2.971 Adhesion, CD molecules, Innate immune response
C3 0.01982 0.499 2.720 Innate immune response, Regulation of immune response
HLA-DPB1 0.00069 0.137 2.561 Adaptive immune response, Antigen processing and presentation
PTPRC 0.04822 0.638 2.535 B-cell proliferation, CD molecules, T-cell differentiation
CX3CR1 0.0117 0.368 2.526 Adaptive immune response, Chemokines and receptors, Microglial cell activation
FUT7 0.00345 0.256 2.488 Leukocyte migration
CTSS 0.01084 0.368 2.440 Adaptive immune response
MSR1 0.03954 0.638 2.267 Basic cell functions, Cell Type specific, CD molecules
FCGR2B 0.04684 0.638 2.132 CD molecules, Regulation of immune response
MEFV 0.00276 0.256 2.085 Innate immune response
CD68 0.02311 0.528 2.074 Basic cell functions, Cell Type specific, CD molecules
ITGAM 0.00035 0.104 2.064 Adhesion, CD molecules, Innate immune response, Receptors involved in phagocytosis
CHIT1 0.04168 0.638 2.006 Basic cell functions, Cell Type specific
GZMK 0.00124 0.163 1.933 Adaptive immune response, Basic cell functions, Cytotoxicity, Innate immune response
ITGB2 0.02745 0.604 1.859 Adhesion, CD molecules, Regulation of immune response
CD53 0.02249 0.528 1.819 CD molecules, Adaptive immune response
CRP 0.04046 0.638 1.793 Acute-phase response, Humoral immune response, Inflammatory response, Innate immune response, Receptors involved in phagocytosis
HLA-DMA 0.04879 0.638 1.687 Adaptive immune response, Antigen processing and presentation, Positive regulation of immune response
CD8A 0.03163 0.638 1.548 Adaptive immune response, Antigen processing and presentation, Cell Type specific, CD molecules, Defense response to virus, T-cell activation, T-cell differentiation
HAVCR2 0.0361 0.638 1.541 Basic cell functions
DUSP6 0.02018 0.499 1.507 Innate immune response
KLRK1 0.01208 0.368 1.478 CD molecules, NK cell functions, Regulation of immune response
LY86 0.00539 0.294 1.466 Innate immune response, Humoral immune response
SPACA3 0.01239 0.368 1.456
TIGIT 0.04384 0.638 1.399 Adaptive immune response, T-cell activation
SELL 0.04335 0.638 1.285 CD molecules, Regulation of immune response
MARCO 0.04824 0.638 0.812 Cell Type specific, Innate immune response
IL1RAP 0.03197 0.638 0.745 Innate immune response
MYD88 0.0474 0.638 0.716 Innate immune response, Toll-like receptor
LTBR 0.01324 0.374 0.702 Chemokines and receptors
DDX43 0.01743 0.470 0.700
IL2RA 0.04836 0.638 0.661 Adaptive immune response, CD molecules, Inflammatory response to antigenic stimulus, Negative regulation of immune response
PLA2G1B 0.01173 0.368 0.579 Positive regulation of immune response
IL23A 0.00561 0.294 0.566 Innate immune response, Interleukins
PSMD7 0.00675 0.308 0.564 CD molecules
IL12RB2 0.04282 0.638 0.550 Adaptive immune response, Cell Type specific, Cytokines and receptors, Th1 orientation
S100B 0.04302 0.638 0.529 Innate immune response
IFNL1 0.00504 0.294 0.270 Cytokines and receptors, Interleukins
IL34 0.00839 0.356 0.248 Innate immune response, Interleukins
HSD11B1 0.00595 0.294 0.177 Basic cell functions, Cell Type specific
PPBP 0.03365 0.638 0.115 Chemokines and receptors
Table 3. DEG CR vs NR (pre-treatment). 45 Significant (p < 0.05) DEGs comparing nanostring immune gene 
expression in pre-treatment samples between CR and NR using unpaired t-test (PR sample was excluded). 
Ordered from high to low fold change (Fc = 2^(mean log2 CR − mean log2 NR expression)).
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Gene p value q value FC (CR vs NR) Annotation
S100A7 0.02973 0.297 14.094 Innate immune response
CXCL9 0.00433 0.245 8.161 Adaptive immune response, Chemokines and receptors, Regulation of inflammatory response, Th1 orientation
LAG3 0.04199 0.297 6.555 Adaptive immune response, CD molecules, Negative regulation of immune response, T-cell activation
CCL5 0.00923 0.245 5.442 Cytokines and receptors, Chronic inflammatory response, Chemokines and receptors, Acute-phase response, Inflammatory response, Innate immune response
IL7R 0.0062 0.245 5.370 Adaptive immune response, CD molecules, Cytokines and receptors
GNLY 0.02575 0.294 4.774 Adaptive immune response, Cell Type specific, Cytotoxicity, Defense response to bacterium, Defense response to fungus
LCN2 0.00015 0.028 4.756 Innate immune response
KLRC2 0.00007 0.026 4.543 CD molecules, NK cell functions
CXCL13 0.02195 0.294 4.526 Adaptive immune response, Cell Type specific, Chronic inflammatory response, Humoral immune response, Chemokines and receptors
SPINK5 0.02524 0.294 4.480 Negative regulation of immune response
CXCR4 0.00936 0.245 4.411 Adaptive immune response, CD molecules, Chemokines and receptors, Co-Regulators of autophagy and apoptosis/cell cycle, T-cell polarization
GZMB 0.02651 0.294 3.997 Adaptive immune response, Basic cell functions, Cell Type specific, Cytotoxicity
RUNX3 0.00994 0.245 3.693 Transcription factors
HLA-G 0.02265 0.294 3.657 Regulation of immune response
IL2RG 0.02719 0.294 3.419 Adaptive immune response, CD molecules, Chemokines and receptors
CCR5 0.00204 0.245 3.309 CD molecules, Cytokines and receptors, T-cell polarization
KLRK1 0.00996 0.245 3.262 CD molecules, NK cell functions, Regulation of immune response
TNFRSF1B 0.03119 0.297 2.966 CD molecules, Chemokines and receptors, TNF superfamily members and their receptors
KLRD1 0.03172 0.297 2.874 Cell Type specific, NK cell functions, Regulation of immune response
HLA-A 0.00419 0.245 2.810 Adaptive immune response, Antigen processing and presentation, Cytotoxicity, Regulation of immune response
CCR7 0.02747 0.294 2.791 CD molecules, Chemokines and receptors, Humoral immune response, Regulation of inflammatory response
CSF2RB 0.01803 0.294 2.693 CD molecules, Chemokines and receptors, Adaptive immune response
TXK 0.0334 0.297 2.662 Adaptive immune response
STAT4 0.0112 0.246 2.413 Adaptive immune response, Cytokines and receptors, Cell Type specific, Transcription factors, Transcriptional regulators, Th1 orientation
ITK 0.00646 0.245 2.281 Adaptive immune response
IL18RAP 0.02112 0.294 2.195 CD molecules, Innate immune response, Th1 orientation
CD48 0.00366 0.245 2.041 CD molecules
GZMA 0.00561 0.245 2.016 Adaptive immune response, Basic cell functions, Cell Type specific, Cytotoxicity
GZMK 0.0156 0.292 1.999 Adaptive immune response, Basic cell functions, Cytotoxicity, Innate immune response
IL12RB2 0.04061 0.297 1.943 Adaptive immune response, Cell Type specific, Cytokines and receptors, Th1 orientation
LCK 0.04913 0.298 1.943 Regulators of T-cell activation
INPP5D 0.04684 0.298 1.918 Negative regulation of immune response
CXCR3 0.04053 0.297 1.792 Adaptive immune response, CD molecules, Chemokines and receptors, T-cell polarization
CD27 0.04115 0.297 1.736 B-cell differentiation, CD molecules
SMPD3 0.02911 0.297 1.720 Basic cell functions, Cell Type specific
TIGIT 0.02512 0.294 1.720 Adaptive immune response, T-cell activation
CASP8 0.02123 0.294 1.636 Innate immune response
NCR1 0.04159 0.297 1.449 Basic cell functions, Cell Type specific, CD molecules, NK cell functions
ICAM2 0.01182 0.246 1.328 Adhesion, CD molecules, Regulation of immune response
LTBR 0.04521 0.298 0.735 Chemokines and receptors
TNFRSF1A 0.03391 0.297 0.634 CD molecules, Chemokines and receptors, TNF superfamily members and their receptors
TLR7 0.03379 0.297 0.633 Microglial cell activation, Innate immune response, Toll-like receptor
PTGS2 0.03499 0.297 0.601 Acute-phase response, Cytokines and receptors
CD63 0.03564 0.297 0.583 CD molecules





CTSG 0.03915 0.297 0.531 Cell Type specific, Defense response to fungus, Positive regulation of immune response
KIR3DL3 0.0223 0.294 0.521 CD molecules, NK cell functions
GPI 0.01482 0.292 0.509 Humoral immune response
HRAS 0.03918 0.297 0.501 Senescence pathway
TREM2 0.02713 0.294 0.477 Humoral immune response
MNX1 0.02152 0.294 0.452 Humoral immune response
Continued
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receptor (CX3CR1), T-cell cytotoxic markers (CD8A, and GZMK), and genes associated with antigen presenta-
tion (HLA-DMA, HLA-DBP1, and HLA-DPA1). Enrichment analysis corroborated the existence of a permissive 
microenvironment in lesions from patients with clinical benefit from imiquimod, substantiated by the activation 
of the antigen processing pathway, which was accompanied by the downregulation of some cytokines such as IFN 
lambda 1 (IFNL1) IL34, and IL23, which is involved in Th-17 signaling (Fig. 1D).
After imiquimod treatment, CR versus NR differed in 57 DEGs (Table 4, Fig. 1B). In this analysis, the PR clus-
tered together with the CR. CR patients had higher levels of several immune genes (Fig. 1C), including chemok-
ines and chemokine receptors (CXCL13, CXCL9, CCL5, CCR5, CXCR3, CCR7, CXCR4), markers of lymphocyte 
activation (LAG3, TXK), NK cells (KLRC2, KLRD1, NCR1), neutrophils (LCN2), and markers of effector func-
tion (GNLY, GZMB, GZMK, GZMA), and innate immunity (TNFRSF1B, IL7R). S100A7, which is involved in the 
regulation of cell cycle progression and proliferation, was also over-expressed. The top enriched pathways in the 
CR group included NK and T-cell functions, chemokines and (immune) regulation (Fig. 1D).
Applying multiple hypothesis correction of a 0.25 false discovery rate (q values provided in Tables 2, 3 and 4), 
yielded 5 genes in the pre-treatment comparison (MPPED1, ITGAM, HLA-DPB1, HLA-DPA1, and GZMK, all 
upregulated in the CR vs NR samples) and 18 genes in the post-treatment comparison (ICAM2, GZMA, CD48, 
ITK, STAT4, HLA-A, KLRK1, RUNX3, CXCR4, KLRC2, LCN2, IL7R, CCL5, CXCL9, and CCR5, upregulated in 
CR vs NR samples and CD1A, USP9Y, and IRAK1, upregulated in NR vs CR samples). The majority of the tran-
scripts upregulated in CR samples relate to chemoattraction, antigen presentation (pre-treatment comparison), 
and cytotoxic mechanisms (post-treatment comparison). No genes passed the 0.25 false discovery rate in the 
pre vs post-treatment comparison likely due to the dilution of the signal caused by the hypo-responsive samples.
Responders to imiquimod treatment had higher levels of T cells and cytotoxic cells. Single sam-
ple gene set enrichment analysis (ssGSEA) was used to estimate the variation in leukocyte subpopulations in 
each sample. Post- vs pre-treatment comparison revealed that overall, imiquimod consistently enhanced T cell 
(p = 0.011) and cytotoxic T cell (p = 0.017) infiltration (Fig. 2A). Before treatment, CR patients had a lower level 
of T central-memory (Tcm) cells (p = 0.038) and a higher level of macrophages (p = 0.0057), T cell (p = 0.039) 
and NKCD56 bright cells (p = 0.012) as compared to NR patients. The relative depletion of Tcm cells could be 
the result of a proportional enrichment of activated T-cell after treatment. Thus, CR patients displayed a baseline 
pre-activated immune microenvironment (Fig. 2B).
In CR patients, there was a strong activation of the cytotoxic response (p = 0.012) accompanied by upregu-
lation of the ICR genes (Fig. 2C) (p = 0.023) and by a switch from immature dendritic cells (iDC) (p = 0.0228) 
to activated dendritic cells (aDCs) (p = 0.096) in post-treatment compared to baseline biopsy. At the individual 
sample level, the magnitude of the cytotoxic response was maximal in responding patients, with similar levels 
among the two CR and the PR (Fig. 3A,B).
A nonsignificant trend for higher CD3, CD8, CD4, and FOXP3 positive cells, as evaluated by immunohis-
tochemistry, was observed in CR vs NR pre-treatment samples and was also present after treatment. However, 
among the responding patients, IHC evaluation detected increase of TILs (consistent across all the markers) only 
in the PR patient (Supplementary Figure 1), who had a local response at the time of the biopsy. This observation 
suggests that molecular profiling might be more sensitive than IHC in detecting changes in the functional orien-
tations of the tumor microenvironment preceding the clinical response.
Responders to imiquimod treatment displayed consistent upregulation of the ICR score. We 
analyzed the immunologic constant of rejection (ICR) score (ie., the mean log2 expression of the ICR genes, 
Fig. 4A,B) across samples, and compared its expression in CR versus NR, pre- and post-treatment. The ICR score 
was significantly higher in the post-treatment CR vs NR samples (p = 0.021) while it did not differ among the 
two categories at baseline (Fig. 4C). Interestingly, the PR sample clustered with the CR samples. The ICR genes 
with significantly higher levels in CR vs NR samples after treatment are shown in Fig. 4D. Most of the ICR genes 
had similar and consistent trends (Supplementary Figure 2). An exception was represented by FOXP3, which 
displayed a non significant lower level in post-treatment CR vs NR samples.
Discussion
This is the first study to characterize the transcriptional changes induced by imiquimod in breast cancer skin 
metastases. The CR samples showed a pre-activated immune microenvironment at baseline, substantiated by 
the enrichment of genes related to antigen processing and a proportional enrichment of T cells, NKCD56 bright 
cells and macrophages. Macrophages have often been shown to be a negative prognostic factor, although M1 
macrophages, which sustain anti-tumor immune response, have been associated with favorable prognosis39,40. 
Gene p value q value FC (CR vs NR) Annotation
USP9Y 0.01048 0.245 0.417 Basic cell functions, Cell Type specific
TNFRSF11B 0.04159 0.297 0.387 TNF superfamily members and their receptors
CD1A 0.00694 0.245 0.322 Basic cell functions, Cell Type specific, CD molecules
FOXJ1 0.02742 0.294 0.290 Cell Type specific, Humoral immune response
CCL28 0.03893 0.297 0.182 Chemokines and receptors
Table 4. DEG CR vs NR (post-treatment). 57 Significant (p < 0.05) DEGs comparing nanostring immune gene 
expression in post treatment samples between CR and NR using unpaired t-test (PR sample was excluded). 
Ordered from high to low fold change (Fc = 2^(mean log2 CR − mean log2 NR expression)).
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Figure 2. Variation in leukocyte subpopulations according to treatment and response status as estimated by 
transcriptomic analysis. (A–C) Forest plots based on fold changes of leukocyte subpopulation enrichment score. 
The enrichment score for each leukocyte subpopulation is calculated by single sample gene set enrichment analysis 
(ssGSEA). Fold changes (FC) are calculated as the ratio of Anti Loge of the enrichment scores. FC > 1 consists of 
increased enrichment score in post- vs pre-treatment sample in (A), increased enrichment score in pre-treatment 
CR vs pre-treatment NR samples in (B), and increased enrichment score in post-treatment complete responder 
vs post-treatment non responder samples (C). p-values are from paired (A) and unpaired (B,C) t-test. The PR was 
not included in the analysis. Red dots highlight the significant findings (p < 0.05, two-tailed).
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However, coordinated activation of the cytotoxic response was observed only after treatment, suggesting that 
despite a permissive microenvironment observed at baseline, tumor destruction in responding lesions requires a 
strong switch from chronic to acute inflammation, which is captured by the ICR genes.
Figure 3. Single sample enrichment scores and consistent changes induced by imiquimod. (A) Dotted 
heatmaps representing the single sample gene set enrichment analysis (ssGSEA) of immune signatures with 
at least 3 genes present in the nanostring data, with labels for response (NR, PR, CR), treatment (post and 
pre), hormone receptor (HR) status, HER2 receptor (HER2) status and ICR classification, samples are ordered 
according treatment and ICR score. (B) Matching dotted heatmap representing the percentage of genes in the 
signature up or downregulated more the 1.5 fold between post and pre-treatment, with inversely regulated genes 
canceling each other out, cut-off at 15%.
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Only a limited proportion of DEG overlaps between pre-treatment CR vs NR, post-treatment CR vs NR, 
and post-vs pre-treatment lesions. The lack of overlap among DEG post- vs pre-treatment with the ones 
detected in the post-treatment CR vs NR comparison might be the result of the dilution of the signal in the 
post-vs pre-treatment comparison due to the inclusion of the NR samples. The differences observed in pre- and 
post-treatment CR vs NR samples might be the consequence of a differential functional activation of the immune 
response at these time points. Baseline CR samples are dominated by a sub-inflamed microenvironment typified 
by the upregulation of antigen-processing related genes, while post-treatment differences are characterized by the 
Figure 4. ICR gene expression according to treatment and response status. (A) Schematic representation of 
ICR genes divided by functional categories. (B) Heatmap based on ICR gene expression, with labels for response 
(NR, PR and CR), treatment (post and pre), hormone receptor (HR) status, HER2 receptor (HER2) status 
and ICR classification. (C) Boxplot of the ICR score expressed as the mean log2 expression of the ICR genes 
according to treatment and response status. (D) Boxplots of representative ICR genes: CD8A (Th1 signaling), 
CXCL9 and CCL5 (CXCR3 and CCR5 signaling), GZMA, GZMB and GNLY (effector functions); p values 
displayed here were calculated using unpaired t-test including only CR and NR. PR data was displayed in the 
boxplots for comparison with the other two categories.
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coordinated activation of cytotoxic mechanisms conducive to immune-mediated rejection. Nevertheless, 40% 
(3/7) of the upregulated genes overlapping between at least two comparisons reflect the activation of a cytotoxic 
response (CD8A, GZMK, KLRK1) while the remaining ones are related to immune modulation. This obser-
vation suggests that the full activation of a pre-existing, yet incomplete, cytotoxic response is critical to induce 
immune-mediated tumor rejection in this setting.
Clinical response to imiquimod treatment was associated with a higher ICR score validating the ICR hypoth-
esis in metastatic breast cancer. The ICR consists of Th-1 signaling genes, CXCR3 and CCR5 chemokines, effector 
function genes, and immune regulatory genes. High expression levels of these genes have been correlated with 
better prognosis in melanoma, ovarian, colorectal, hepatocellular, lung, as well as breast cancer10,12,14, and in 
lesions more likely to respond to immunotherapy10,15–17. Recently, Ayers et al. identified and validated an immune 
gene signature correlating with clinical benefit to PD1 blockade41. This 18-gene signature includes IFN-γ–induc-
ible genes (STAT1, HLA-E), transcripts related to antigen presentation (HLA-DQA1, HLA-DRB1, PSMB10, 
CMKLR1), chemokines and chemokine ligands (CCL5, CXCL9, CXCR6), cytotoxic activity (CD8A, NKG7), 
and regulatory functions (TIGIT, LAG3, CD274 (PDLI), CD276, and PDCD1LG2(PDL2)) and as such highly 
overlaps with the ICR genes42.
LAG-3 was identified as one of the DEGs upregulated with a 6.6 fold change in the CR group post-treatment. 
LAG-3 is a receptor expressed by activated T lymphocytes and is considered a marker of T cell exhaustion lead-
ing to reduced effector function and expression of inhibitory receptors43. Blockade of LAG-3 is hypothesized 
to synergize with other immune checkpoint inhibitors such as anti-PD-144. Phase II data of imiquimod with 
nab-paclitaxel also showed that patients with a poor clinical response had higher circulating levels of PD-1+ T 
cells suggesting that combination therapy with anti-PD-1 and/or anti-LAG-3 may increase treatment responses33. 
Previous clinical trial data, of mostly estrogen receptor positive metastatic breast cancer, suggest that when com-
bined with chemotherapy, a LAG-3 inhibitor in metastatic breast cancer can increase the number of activated 
monocytes, dendritic cells, NK cells and CD8 T cells with promising response rates45. Our data suggests that 
LAG-3 may play an important role in breast cancer skin metastases as well and LAG-3 inhibition and PD-1 inhi-
bition should be considered in combination with imiquimod as possible treatment modalities.
Interestingly, the PR sample had the same immune gene expression signature post-treatment (clustering 
together with the 2 CR samples) as the complete responders (Fig. 1C). Our subsequent long-term analyses of 
tumor antigen-specific immune responses point to the important role of imiquimod treatment inducing the 
adaptive response, which then got augmented during endocrine therapy in both patients as they continued to 
derive clinical benefit and entered a long-lasting CR36. This likely explains the unexpected and durable complete 
response from fulvestrant since a previous large phase 3 study of fulvestrant monotherapy demonstrated that a 
complete response is very rare46. This further suggests that the genes upregulated by imiquimod are associated 
with long term immunogenic effects which can improve the efficacy of subsequent therapies. Whereas upregu-
lation of ICR genes has been previously correlated with better response to chemotherapy and trastuzumab29,47, 
our data suggests that activation of these pathways may also improve response to subsequent hormonal therapy.
Limitations of our study are the small number of patients and the short duration of treatment. The delayed 
CR in two patients who displayed immune activation within the metastases after eight weeks of treatment with 
imiquimod suggests the possibility that a longer treatment might increase response rates. Genes differentially 
expressed detected by univariate analysis are subject to false discovery. The possibility to incur into a Type I error 
(i.e., the rejection of a true null hypothesis) is partially attenuated by the use of the integrative pipeline presented 
here. By combining deconvolution and enrichment analyses, more permissive cut-off p values can be used to 
detect biological relevant phenomena. Nevertheless, this dataset should be considered as a discovery set, and 
further validation using orthogonal platforms as deep phenotyping and proteomic approaches are warranted.
The strength of this study is the use of gene array analysis in paired samples derived from a prospective clinical 
trial with long-term follow-up of patients. This sensitive technique for characterizing immune changes induced 
by imiquimod treatment was able to detect at 8 weeks intratumoral changes associated with not only immediate 
but also future clinical benefit, which could not be derived from histologic analysis35.
Metastatic breast cancer, especially with cutaneous metastases, remains very difficult to treat. Long-term clin-
ical response to therapy in metastatic cancer is rare. Promoting immunogenicity in the tumor microenvironment 
may enhance efficacy of other therapies such as chemotherapy, endocrine therapy, targeted therapies or even 
newer immunotherapeutics. Imiquimod has been shown to be a potent activator of the innate immune system, 
which then supports adaptive immune response in cancer, and we demonstrate that this is the case in metastatic 
breast cancer as well. Encouragingly, although hormone receptor positive breast cancer appears to be the least 
immunogenic type of breast cancer34, we have shown that imiquimod can induce a robust anti-tumor immune 
response leading to clinical response in the three patients with hormone receptor positive disease described here. 
This is in line with a recent report of successful immunotherapy in a patient with metastatic hormone receptor 
positive breast cancer48. Future trials are needed to investigate the use of imiquimod in combination with other 
therapies.
Data Availability
The normalized Nanostring data used in the current study is available as Supplementary File 1.
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